• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Neuro-Oncology >P09.23 Tumor Treating Fields delivery using second generation Optune® system for glioblastoma treatment: patient experience and compliance
【2h】

P09.23 Tumor Treating Fields delivery using second generation Optune® system for glioblastoma treatment: patient experience and compliance

机译：P09.23使用第二代Optune®系统治疗胶质母细胞瘤的肿瘤治疗区域：患者的经验和依从性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

>Significance and Background: Tumor Treating Fields (TTFields) are non-invasive, low-intensity electric fields with anti-mitotic activity delivered using the Optune® System, which is approved for the treatment of adult patients with newly diagnosed and recurrent supratentorial glioblastoma (GBM). TTFields are delivered via 4 transducer arrays that are applied directly to the scalp to target the tumor. The first generation Optune® system consisting of a field generator, portable lithium batteries, carrying bag, and transducer arrays weighed approximately ~ 2.7 Kg (6 pounds). The system has been redesigned to improve the convenience and manageability of TTFields therapy for GBM patients. The second generation Optune® System uses new digital signal generation technology to reduce the size and weight to ~ 1.2 Kg (2.7 pounds) including the battery, which may positively affect patient convenience and compliance with treatment. >Purpose: To understand the effect of size and weight advantages of the second generation Optune® System on patient satisfaction, compliance (time on therapy), and usability. >Interventions: Ten GBM patients (N=10, male = 8, female = 2, median age: 52.9 years [31-79]) were monitored at multiple time points over the first month of transitioning to the second generation Optune® System using a questionnaire assessing the convenience and ease of daily usage as well as duration of daily use and frequency of complications associated with usage (alarms). >Evaluation: A 10 point numerical analog scale was utilized to assess feedback at baseline (on the original system) and at 5 specific time points over the first month of second generation Optune System usage. Patient feedback highlighted the benefits of enhanced features such as quieter operation and portability. >Discussion: Overall, patients were very satisfied with the new system in terms of convenience and usability and experienced less number of alarms. Patient compliance using the second generation Optune® System was maintained and in most cases improved compared with the original Optune® System. >Innovation: TTFields treatment that target compliance rates of 75% (18 hours per day) improve survival outcomes as observed in GBM clinical trials. The results of this patient survey indicate that the improved size, weight and convenience of the second generation Optune® System help patients comply with daily treatment duration goals.
机译：>意义和背景：肿瘤治疗场（TTFields）是使用Optune ®系统提供的具有抗有丝分裂活性的无创，低强度电场，已被批准用于成人新诊断和复发性幕上胶质母细胞瘤（GBM）的治疗。 TTFields通过4个换能器阵列传递，这些换能器阵列直接应用于头皮以靶向肿瘤。第一代Optune ®系统由一个磁场发生器，便携式锂电池，便携袋和传感器阵列组成，重约2.7 Kg（6磅）。该系统已经过重新设计，以提高GBM患者的TTFields治疗的便利性和可管理性。第二代Optune ®系统使用新的数字信号生成技术将包括电池在内的尺寸和重量减小到约1.2 Kg（2.7磅），这可能对患者的便利性和治疗依从性产生积极影响。 >目的：了解第二代Optune ®系统的尺寸和重量优势对患者满意度，依从性（治疗时间）和可用性的影响。 >干预措施：在过渡至肝癌的第一个月中的多个时间点监测了十名GBM患者（N = 10，男性= 8，女性= 2，中位年龄：52.9岁[31-79]）。使用问卷调查的第二代Optune ®系统评估日常使用的便利性和便利性，日常使用的持续时间以及与使用相关的并发症（报警）的频率。 >评估：在第二代Optune系统使用的第一个月内，使用10分数值模拟量表评估了基线（在原始系统上）和5个特定时间点的反馈。患者的反馈强调了增强功能（例如更安静的操作和便携性）的好处。 >讨论：总体而言，患者对新系统的便利性和可用性非常满意，并且警报次数更少。与原始的Optune ®系统相比，使用第二代Optune ®系统的患者依从性得以保持，并且在大多数情况下得到了改善。 >创新：针对GBM临床试验中观察到的达到75％（每天18小时）依从率的TTFields治疗可提高生存率。这项患者调查的结果表明，第二代Optune ®系统的尺寸，重量和便利性得到了改善，可帮助患者达到每日治疗持续时间的目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号